Biotechnology
Chemicals
Manufacturing

Codexis

$18.74
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.76 (-3.90%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Codexis and other stocks, options, ETFs, and crypto commission-free!

About

Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. Read More The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Employees
132
Headquarters
Redwood City, California
Founded
2002
Market Cap
1.06B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
387.92K
High Today
$19.28
Low Today
$18.62
Open Price
$19.19
Volume
104.70K
52 Week High
$23.05
52 Week Low
$12.85

Collections

Biotechnology
Chemicals
Manufacturing
Pharmaceutical
Medical
Technology
Engineering
Health

News

Yahoo FinanceMay 16

Who Has Been Selling Codexis, Inc. Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders have sold shares. So we'll take a look at whether insiders have been buying or selling shares in Codexis, Inc. (NASDAQ:CDXS). What Is Insider Selling? Scroll to continue with content Ad It's quite normal to see company insiders, such as board members, trading in company stock, from time to...

310
ReutersMay 15

BRIEF-Codexis Inc - Announces Signing Of A Codeevolver Platform Agreement With Novartis

May 15 (Reuters) - Codexis Inc: * CODEXIS INC - ANNOUNCES SIGNING OF A CODEEVOLVER PLATFORM AGREEMENT WITH NOVARTIS * CODEXIS - UNDER TERMS, NOVARTIS WILL PAY CO UPFRONT PAYMENT, MILESTONE PAYMENTS UPON SATISFACTORY COMPLETION OF TECHNOLOGY TRANSFER * CODEXIS - WILL BE ELIGIBLE TO GET PAYMENTS FOR ACTIVE PHARMACEUTICAL INGREDIENTS MADE WITH ENZYMES DEVELOPED BY NOVARTIS USING CODEEVOLVER TECHNOLOGY * CODEXIS INC - RECEIVES CERTAIN RIGHTS FOR FUTURE PURCHASES OF ENZYMES DEVELOPED & SOURCED BY NOVARTIS US...

119
Yahoo FinanceMay 15

Codexis Announces CodeEvolver® Technology Transfer and License Agreement with Global Pharmaceutical Leader

Third CodeEvolver® licensing agreement with a major pharma company REDWOOD CITY, Calif., May 15, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (CDXS), a leading protein engineering company, announces the signing of a CodeEvolver® platform agreement with Novartis. Under the terms of the agreement, Codexis has granted a non-exclusive license to its proprietary CodeEvolver® protein engineering platform technology to Novartis to develop novel performance enzymes for use in manufacturing pharmaceutical products. Upon ...

8

Earnings

-$0.17
-$0.09
-$0.02
$0.06
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.